Literature DB >> 19762145

Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation.

Katherine L Meyer-Siegler1, Jacob Cox, Lin Leng, Richard Bucala, Pedro L Vera.   

Abstract

Mounting evidence suggests that the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF) may serve as an important link between chronic inflammation and carcinogenesis as evidenced by the increase in serum MIF found in patients with various cancers. The present study identifies anti-thrombin III (ATIII) as an endogenous MIF binding protein, which reduces MIF biological activity. Serum MIF in bladder cancer patients (TCC stage II, n=50) was increased when compared to normal patients (n=50), while ATIII-MIF complexes were decreased in bladder cancer patient serum. These data suggest that increased circulating levels of bioactive MIF are present in bladder cancer patient serum. Published by Elsevier Ireland Ltd.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19762145      PMCID： PMC2832085          DOI： 10.1016/j.canlet.2009.08.025

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  41 in total

1.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search.

Authors:  Andrew Keller; Alexey I Nesvizhskii; Eugene Kolker; Ruedi Aebersold
Journal:  Anal Chem       Date:  2002-10-15       Impact factor: 6.986

2.  Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.

Authors:  Yue Cao; Ake Lundwall; Virgil Gadaleanu; Hans Lilja; Anders Bjartell
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

3.  Protection from septic shock by neutralization of macrophage migration inhibitory factor.

Authors:  T Calandra; B Echtenacher; D L Roy; J Pugin; C N Metz; L Hültner; D Heumann; D Männel; R Bucala; M P Glauser
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

4.  Urine macrophage migration inhibitory factor concentrations as a diagnostic tool in human renal allograft rejection.

Authors:  F G Brown; D J Nikolic-Paterson; S J Chadban; J Dowling; M Jose; C N Metz; R Bucala; R C Atkins
Journal:  Transplantation       Date:  2001-06-27       Impact factor: 4.939

Review 5.  Macrophage migration inhibitory factor.

Authors:  Elias Lolis; Richard Bucala
Journal:  Expert Opin Ther Targets       Date:  2003-04       Impact factor: 6.902

6.  Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells.

Authors:  Christian Oelschläger; Jürgen Römisch; Anne Staubitz; Harald Stauss; Boris Leithäuser; Harald Tillmanns; Hans Hölschermann
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

7.  Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma.

Authors:  Katherine L Meyer-Siegler; Michael A Bellino; Myron Tannenbaum
Journal:  Cancer       Date:  2002-03-01       Impact factor: 6.860

Review 8.  Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases.

Authors:  Steven T Olson; Yung-Jen Chuang
Journal:  Trends Cardiovasc Med       Date:  2002-11       Impact factor: 6.677

9.  Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator.

Authors:  Nikolai Petrovsky; Luis Socha; Diego Silva; Ashley B Grossman; Christine Metz; Richard Bucala
Journal:  Immunol Cell Biol       Date:  2003-04       Impact factor: 5.126

10.  Substance P increases cell-surface expression of CD74 (receptor for macrophage migration inhibitory factor): in vivo biotinylation of urothelial cell-surface proteins.

Authors:  Katherine L Meyer-Siegler; Shen-Ling Xia; Pedro L Vera
Journal:  Mediators Inflamm       Date:  2009-03-22       Impact factor: 4.711
View more
  4 in total

1.  Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast.

Authors:  Yoonsang Cho; Gregg V Crichlow; Jon J Vermeire; Lin Leng; Xin Du; Michael E Hodsdon; Richard Bucala; Michael Cappello; Matt Gross; Federico Gaeta; Kirk Johnson; Elias J Lolis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-08       Impact factor: 11.205

2.  Pleiotropic role of macrophage migration inhibitory factor in cancer.

Authors:  Maheedhara R Guda; Matthew A Rashid; Swapna Asuthkar; Anvesh Jalasutram; John L Caniglia; Andrew J Tsung; Kiran K Velpula
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

3.  Thrombin induces macrophage migration inhibitory factor release and upregulation in urothelium: a possible contribution to bladder inflammation.

Authors:  Pedro L Vera; Terra E Wolfe; Alexander E Braley; Katherine L Meyer-Siegler
Journal:  PLoS One       Date:  2010-12-31       Impact factor: 3.240

4.  Informative gene selection and the direct classification of tumors based on relative simplicity.

Authors:  Yuan Chen; Lifeng Wang; Lanzhi Li; Hongyan Zhang; Zheming Yuan
Journal:  BMC Bioinformatics       Date:  2016-01-20       Impact factor: 3.169
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.